Evidence map›Paper›PMID 35006963›Full record

ReviewACS applied bio materials2021

Nanoplasmonic Sensor Approaches for Sensitive Detection of Disease-Associated Exosomes.

Pouya Amrollahi, Wenshu Zheng, Chandler Monk, Chen-Zhong Li, Tony Ye Hu

Open access · hybridAbstract readReview
In one paragraph

Review in ACS applied bio materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Pouya AmrollahiCenter of Cellular and Molecular Diagnosis, Tulane University, New Orleans, Louisiana 70118, United States.
Wenshu ZhengCenter of Cellular and Molecular Diagnosis, Tulane University, New Orleans, Louisiana 70118, United States.
Chandler MonkCenter of Cellular and Molecular Diagnosis, Tulane University, New Orleans, Louisiana 70118, United States.
Chen-Zhong LiCenter of Cellular and Molecular Diagnosis, Tulane University, New Orleans, Louisiana 70118, United States.
Tony Ye HuCenter of Cellular and Molecular Diagnosis, Tulane University, New Orleans, Louisiana 70118, United States.ORCID 0000-0002-5166-4937
Tulane University · US

Funding

Interdisciplinary Predoctoral Training in BioinnovationT32EB027632 · NIBIB · TULANE UNIVERSITY OF LOUISIANA · PI GAVER, DONALD P. · 2019 to 2023
$813k
NIBIB NIH HHS T32 EB027632
6 · The paper itself

Abstract

Exosomes are abundantly secreted by most cells that carry membrane and cytosolic factors that can reflect the physiologic state of their source cells and thus have strong potential to serve as biomarkers for early diagnosis, disease staging, and treatment monitoring. However, traditional diagnostic or prognostic applications that might use exosomes are hindered by the lack of rapid and sensitive assays that can exploit their biological information. An array of assay approaches have been developed to address this deficit, including those that integrate immunoassays with nanoplasmonic sensors to measure changes in optical refractive indexes in response to the binding of low concentrations of their targeted molecules. These sensors take advantage of enhanced and tunable interactions between the electron clouds of nanoplasmonic particles and structures and incident electromagnetic radiation to enable isolation-free and ultrasensitive quantification of disease-associated exosome biomarkers present in complex biological samples. These unique advantages make nanoplasmonic sensing one of the most competitive approaches available for clinical applications and point-of-care tests that evaluate exosome-based biomarkers. This review will briefly summarize the origin and clinical utility of exosomes and the limitations of current isolation and analysis approaches before reviewing the specific advantages and limitations of nanoplasmonic sensing devices and indicating what additional developments are necessary to allow the translation of these approaches into clinical applications.

Indexed as

ExosomesBiological AssayBiomarkersImmunoassayRefractometryBiomarkersbiosensorexosomesextracellular vesiclesmetamaterialnanoplasmonics

Identifiers

PMID35006963
PMCPMC9130051
OpenAlexW3187353854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.